Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Prehabilitación Multicomponente en Adultos Mayores con Cáncer de Mama (PREHAB-BC65)

24 de septiembre de 2026 actualizado por: Nicolás Martínez Velilla, Fundacion Miguel Servet

Multidimensional Oncogeriatric Prehabilitation in Older Adults With Breast Cancer: A Randomized Controlled Trial Integrating Frailty and Biomarker Assessment

Older adults with breast cancer frequently present with frailty, decreased functional reserve, and increased risk of postoperative complications. Prehabilitation programs have emerged as a promising strategy to improve physical function and clinical outcomes; however, evidence in geriatric oncology remains limited, particularly regarding the role of biological markers in predicting response to such interventions.

This study aims to evaluate the effectiveness of a multicomponent prehabilitation program in older adults with breast cancer, focusing on functional status, clinical outcomes, and quality of life. In addition, the study seeks to characterize biological markers associated with frailty and treatment response, with the goal of identifying potential predictors of benefit from prehabilitation.

Participants will undergo a structured prehabilitation intervention including physical exercise, nutritional optimization, and comprehensive geriatric assessment. Clinical, functional, and biomarker data will be collected longitudinally.

The results of this study may contribute to improving personalized care strategies in geriatric oncology and to identifying patients who are most likely to benefit from prehabilitation programs.

Descripción general del estudio

Descripción detallada

This study is a prospective, randomized, controlled, single-blind clinical trial designed to evaluate the effectiveness of a multicomponent prehabilitation program in older adults with breast cancer, incorporating biological characterization to explore predictors of treatment response.

The trial will be conducted at the Navarre University Hospital (Pamplona, Spain). A total of 90 ambulatory patients aged 65 years or older with a confirmed diagnosis of breast cancer will be recruited and randomly assigned in a 1:1:1 ratio to usual care, a home-based multicomponent exercise program based on the Vivifrail methodology, or a supervised hospital-based intervention. All participants will undergo baseline frailty screening followed by a comprehensive geriatric assessment to characterize functional, cognitive, nutritional, and clinical status. Assessments will be repeated at predefined time points throughout the perioperative period and during follow-up.

The intervention is structured into preoperative and postoperative phases and includes individualized multicomponent exercise, nutritional optimization, and targeted management of geriatric syndromes. The hospital-based intervention consists of supervised sessions over six weeks (including a 2-week preoperative phase and a 4-week postoperative phase), while the home-based intervention is adapted to baseline functional status.

Clinical, functional, and biological data will be collected longitudinally to evaluate the impact of the intervention and to identify predictors of clinical outcomes and treatment response.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

90

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

Ubicaciones de estudio

    • Navarre
      • Pamplona, Navarre, España, 31008
        • Reclutamiento
        • Hospital Universitario de Navarra
        • Contacto:
        • Contacto:
        • Investigador principal:
          • Nicolás Martínez Velilla, MD, PhD
        • Sub-Investigador:
          • Bernardo Abel Cedeño Veloz, MD, PhD
        • Sub-Investigador:
          • Susana de la Cruz Sánchez, MD
        • Sub-Investigador:
          • Sara Esteban Gordillo, MD
        • Sub-Investigador:
          • Natalia Moras Pérez, MD
        • Sub-Investigador:
          • Fabricio Zambom Ferraresi, PhD
        • Sub-Investigador:
          • Marta Lorente Escudero, MD
        • Sub-Investigador:
          • Lucía Lozano Vicario, MD, PhD

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

65 años y mayores (Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Age ≥65 years
  • Diagnosis of breast cancer requiring elective surgery with curative intent
  • Candidate for prehabilitation program before surgery
  • Ability to walk (with or without assistive devices)
  • Ability to provide informed consent

Exclusion Criteria:

  • Urgent or emergency surgery
  • Severe cognitive impairment precluding participation in the intervention
  • Severe functional dependency (e.g., bedridden patients)
  • Medical contraindication to physical exercise
  • Life expectancy <3 months

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Sin intervención: Usual Care

Participants receive standard clinical care according to routine practice, including management by oncology and surgical teams. Identified geriatric conditions are communicated to the treating physician for appropriate management.

Experimental: Home-based Multicomponent Prehabilitation (Vivifrail)

Participants perform a home-based multicomponent exercise program based on the Vivifrail methodology, including strength, endurance, balance, and flexibility training over six weeks, comprising a 2-week preoperative phase and a 4-week postoperative phase. The program is tailored according to baseline functional status and supported by caregiver supervision. Participants also receive comprehensive geriatric assessment and nutritional optimization.

Participants perform a structured home-based multicomponent exercise program based on the Vivifrail methodology, including strength, endurance, balance, and flexibility training over six weeks. The program is individualized according to baseline functional status.

Participants undergo comprehensive geriatric assessment with targeted interventions including nutritional optimization, medication review, and management of geriatric syndromes.

Experimental: Supervised Multicomponent Prehabilitation

Participants receive a supervised multicomponent exercise program delivered in the hospital setting, including aerobic, resistance, balance, and flexibility training over six weeks, including a 2-week preoperative phase and a 4-week postoperative phase. The intervention is combined with comprehensive geriatric assessment, nutritional optimization, and individualized management of geriatric syndromes.

Participants undergo comprehensive geriatric assessment with targeted interventions including nutritional optimization, medication review, and management of geriatric syndromes.

Participants receive a structured, supervised multicomponent exercise program delivered in a hospital setting, including aerobic, strength, balance, and flexibility training over six weeks.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in physical function assessed by Short Physical Performance Battery (SPPB)
Periodo de tiempo: Baseline to the end of the 6-week intervention period

Physical function will be assessed using the Short Physical Performance Battery (SPPB), a validated tool in older adults (score range 0-12, higher scores indicate better performance). The primary outcome will be the change in SPPB score from baseline to the end of the 6-week intervention period.

Baseline to the end of the 6-week intervention period

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Incidence of postoperative complications
Periodo de tiempo: Within 30 days after surgery

Occurrence of postoperative complications within 30 days after surgery, classified according to the Clavien-Dindo classification.

Within 30 days after surgery
Length of hospital stay
Periodo de tiempo: From date of surgery until hospital discharge, with a maximum follow-up of 30 days postoperatively

Number of days from surgery to hospital discharge.

From date of surgery until hospital discharge, with a maximum follow-up of 30 days postoperatively
Functional decline after surgery
Periodo de tiempo: Baseline to 30 days after surgery

Functional decline defined as a decrease in the Short Physical Performance Battery (SPPB) score (range 0 to 12, with higher scores indicating better physical performance) or loss of independence in activities of daily living compared to baseline.

Baseline to 30 days after surgery
Health-related quality of life
Periodo de tiempo: Baseline to 30 days after surgery

Health-related quality of life assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30; scores transformed to a 0-100 scale, where higher scores indicate better functioning or worse symptoms depending on the domain).

Baseline to 30 days after surgery
Adherence to the intervention
Periodo de tiempo: During the 6-week intervention period

Percentage of prescribed exercise sessions completed by participants.

During the 6-week intervention period

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Director de estudio: Marta Lorente Escudero, MD, Navarre Health Service (SNS-O), Navarre University Hospital (HUN), Pamplona, Spain

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

4 de diciembre de 2024

Finalización primaria (Estimado)

1 de marzo de 2027

Finalización del estudio (Estimado)

1 de junio de 2028

Fechas de registro del estudio

Enviado por primera vez

31 de marzo de 2026

Primero enviado que cumplió con los criterios de control de calidad

13 de abril de 2026

Publicado por primera vez (Actual)

15 de abril de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

29 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

24 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

Individual participant data will not be shared due to data protection regulations and institutional policies. De-identified data may be available from the corresponding author upon reasonable request, subject to ethical approval and data sharing agreements.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir